New combo therapy shows promise for Tough-to-Treat prostate cancer
NCT ID NCT07047118
First seen Oct 31, 2025 · Last updated May 19, 2026 · Updated 33 times
Summary
This study tests whether adding an experimental drug (JSB462) to a standard targeted radiation therapy (lutetium-177) works better than the radiation therapy alone for men with a specific type of advanced prostate cancer that no longer responds to hormone therapy. About 138 men whose cancer has spread and shows a certain marker (PSMA-positive) will take part. The goal is to see if the combination can shrink tumors or slow the disease, and to find the best dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC CANCER, CASTRATION-RESISTANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope National Medical
Duarte, California, 91010, United States
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NYU Laura and Isaac Perlmutter Cancer Center
New York, New York, 10016, United States
-
Novartis Investigative Site
Darlinghurst, New South Wales, 2010, Australia
-
Novartis Investigative Site
Adelaide, South Australia, 5000, Australia
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Innsbruck, Tyrol, 6020, Austria
-
Novartis Investigative Site
Linz, 4020, Austria
-
Novartis Investigative Site
Vienna, 1090, Austria
-
Novartis Investigative Site
Burnaby, British Columbia, V5G 4P3, Canada
-
Novartis Investigative Site
Montreal, Quebec, H3T 1E2, Canada
-
Novartis Investigative Site
Beijing, 100034, China
-
Novartis Investigative Site
Beijing, 100036, China
-
Novartis Investigative Site
Olomouc, 779 00, Czechia
-
Novartis Investigative Site
Prague, 150 06, Czechia
-
Novartis Investigative Site
Brest, 29200, France
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Tours, 37044, France
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Rostock, 18057, Germany
-
Novartis Investigative Site
Afula, 1834111, Israel
-
Novartis Investigative Site
Beersheba, 8457108, Israel
-
Novartis Investigative Site
Haifa, 3109601, Israel
-
Novartis Investigative Site
Jerusalem, 9103102, Israel
-
Novartis Investigative Site
Petah Tikva, 4941492, Israel
-
Novartis Investigative Site
Ramat Gan, 5265601, Israel
-
Novartis Investigative Site
Genova, GE, 16132, Italy
-
Novartis Investigative Site
Roma, RM, 00128, Italy
-
Novartis Investigative Site
Nijmegen, Gerlderland, 6532 SZ, Netherlands
-
Novartis Investigative Site
Hoofddorp, 2134 TM, Netherlands
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Seoul, 03722, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
Granada, Andalusia, 18014, Spain
-
Novartis Investigative Site
El Palmar, Murcia, 30120, Spain
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Seville, 41013, Spain
-
Novartis Investigative Site
Taipei, 103616, Taiwan
-
Providence Saint Johns Health Ctr
Santa Monica, California, 90404, United States
-
Rocky Mountain Cancer Centers
Denver, Colorado, 80218, United States
-
Texas Oncology Sammons Cancer Center
Dallas, Texas, 78246, United States
-
Univ of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15232, United States
-
Urology San Antonio
San Antonio, Texas, 78229, United States
-
XCancer Omaha LLC
Omaha, Nebraska, 68130, United States
-
Yale University School Of Medicine
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.